Top Gilead cancer researcher jumps to a startup as Dan Chen exits; Ardelyx gets that CRL we've been waiting for
Chris Takimoto, the former CMO at Forty Seven who completed a stint as SVP of oncology R&D at Gilead after the buyout, is moving on …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
